Kintor Pharmaceutical Limited has issued the proxy form and agenda for its annual general meeting scheduled for 18 June 2026 in Suzhou, Jiangsu Province.
Key items to be tabled:
1. Financial Statements • Shareholders will vote on the adoption of the audited consolidated results for the year ended 31 December 2025, together with the accompanying directors’ and independent auditor’s reports.
2. Board Composition and Remuneration • Re-election of Executive Director Dr. Xiang Ni. • Re-election of Non-executive Directors Mr. Yunfei Chen and Ms. Geqi Wei. • Authorisation for the Board to set directors’ remuneration.
3. Auditor Appointment • Proposal to appoint Rongcheng (Hong Kong) CPA Limited as the new external auditor until the next AGM, with the Board authorised to determine its fee.
4. Share Issuance and Repurchase Authorities • General mandate permitting the Board to issue additional shares up to 20% of the company’s issued share capital. • Separate mandate allowing repurchase of up to 10% of issued shares. • Extension clause enabling any shares bought back under the repurchase mandate to be added to the issuance limit.
Practical arrangements: shareholders must lodge completed proxy forms with Computershare Hong Kong Investor Services by 09:00 a.m. on 16 June 2026, 48 hours before the meeting. Attendance and voting in person remain available to shareholders despite lodging a proxy.
Comments